We are analyzing https://link.springer.com/article/10.1007/s00432-021-03896-w.

Title:
Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial | Journal of Cancer Research and Clinical Oncology
Description:
Introduction While some clinical studies have shown that PD-1 and PD-L1 can also be an effective neoadjuvant treatment for early-stage non-small cell lung cancer (NSCLC), no evidence has been available for the use of the PD-1 inhibitor sintilimab combined with chemotherapy as a neoadjuvant treatment for potentially resectable NSCLC in the Chinese population. Methods This prospective, single-center, single-arm, phase 2 clinical trial (registration number: NCT04326153) included treatment-naive patients with potentially resectable NSCLC (stage IIIA/IIIB) who received sintilimab plus nab-paclitaxel and carboplatin for two to three cycles before systematic nodal dissection 30 to 45 days after neoadjuvant treatment. After surgery, patients needed to complete two cycles of adjuvant chemoimmunotherapy (sintilimab + nab-paclitaxel + carboplatin). The primary endpoint was disease-free survival rate at 24 months, whereas secondary endpoints included major pathological response (MPR) and pathologic complete response (pCR) rates, the proportion of patients who achieved tumor downstaging, overall survival, objective response rate (ORR), and adverse effects. PD-L1 status before and after treatment was also determined. Results Among the 20 patients who received neoadjuvant chemoimmunotherapy, 16 underwent radical resection. The disease control rate and ORR were 90% and 70%, respectively. Among the 16 patients who underwent surgery, 10 (62.5%) and 5 (31.25%) achieved MPR and pCR, respectively. Squamous cell NSCLC exhibited superior response rates compared to adenocarcinoma (pCR 35.7% vs. 0%). Moreover, 14 patients (70%) experienced grade 1 or 2 neoadjuvant treatment-related adverse events (TRAEs), whereas 6 (30%) experienced grade 3 TRAEs. Bronchopleural fistula (BPF) was found in the current study as an adverse reaction of concern. The rate of BPF was 20% (4/20), of which three patients were in grade 1–2, and one patient died. The occurrence of BPF had no significant correlation with basic disease history, nutritional status, anemia, hypoalbuminemia, surgical procedure, pathological remission, and PD-L1 expression. However, during neoadjuvant treatment, no adverse events prompted dose reduction, treatment discontinuation, surgery delay, or death. Although PD-L1 expression may change after chemoimmunotherapy, no regular pattern was noted. PD-L1 expression, neither at baseline nor after neoadjuvant chemoimmunotherapy, was associated with pathological remission. Conclusions The current study found similar ORR, slightly lower MPR and pCR rates, and lower grade 3 TRAEs among patients with potentially resectable stage IIIA/IIIB NSCLC compared to the NADIM trial, as well as a greater ORR, MPR rate, pCR rate, and grade 3 TRAEs compared to Gao’s study involving sintilimab for Chinese patients with resectable stage IA–IIIB NSCLC. Though neoadjuvant chemoimmunotherapy had been found to promote a high risk of BPF for patients with stage IIIA/IIIB disease, it offered greater potential for radical cure. Therefore, the current study suggests that neoadjuvant chemoimmunotherapy can be a safe approach in increasing the efficiency of treatment and hopefully improving the prognosis of patients with potentially resectable locally advanced NSCLC.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Health & Fitness
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,626,432 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't tell how the site generates income.

Websites don't always need to be profitable; some serve as platforms for education or personal expression. Websites can serve multiple purposes. And this might be one of them. Link.springer.com has a revenue plan, but it's either invisible or we haven't found it.

Keywords {🔍}

article, cancer, pubmed, google, scholar, lung, neoadjuvant, patients, cell, resectable, nonsmall, cas, chemotherapy, nsclc, response, oncol, data, treatment, phase, sintilimab, thorac, central, clinical, stage, trial, study, surgery, pathological, adverse, nonsmallcell, clin, management, singlearm, chemoimmunotherapy, rate, bronchopleural, fistula, ann, surg, jilin, potentially, liu, survival, pcr, events, advanced, access, privacy, cookies, content,

Topics {✒️}

stage iiia-n2 egfr-mutant month download article/chapter small-cell lung cancer stage iiia/iiib disease william wn jr small-cell lung cancers t-cell checkpoint inhibitors stage ii-iii stage iiia/iiib disease-free survival rate phase ii trial included treatment-naive patients advanced squamous nsclc lung cancer surgery major pathological response resectable lung cancer clinical oncology aims potentially resectable nsclc lung cancer resection resected lung cancer full article pdf privacy choices/manage cookies open window thoracostomy kewei ma systematic meta-analysis william wn zhiguang yang resectable locally advanced objective response rate pathologic complete response low-dose radiotherapy article sun stage iii sintilimab + nab-paclitaxel + carboplatin common terminology criteria response evaluation criteria neoadjuvant checkpoint blockade basic disease history advanced solid tumors disease control rate european economic area shi qiu code availability french database epithor erlotinib versus gemcitabine pathological effect interpretation clinical risk model neoadjuvant pd-1 inhibitor article journal xiaobo ma

Questions {❓}

Chatwal MS, Tanvetyanon T (2018) Combination chemotherapy and immunotherapy in metastatic non-small cell lung cancer: a setback for personalized medicine?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial
         description:While some clinical studies have shown that PD-1 and PD-L1 can also be an effective neoadjuvant treatment for early-stage non-small cell lung cancer (NSCLC), no evidence has been available for the use of the PD-1 inhibitor sintilimab combined with chemotherapy as a neoadjuvant treatment for potentially resectable NSCLC in the Chinese population. This prospective, single-center, single-arm, phase 2 clinical trial (registration number: NCT04326153) included treatment-naive patients with potentially resectable NSCLC (stage IIIA/IIIB) who received sintilimab plus nab-paclitaxel and carboplatin for two to three cycles before systematic nodal dissection 30 to 45 days after neoadjuvant treatment. After surgery, patients needed to complete two cycles of adjuvant chemoimmunotherapy (sintilimab + nab-paclitaxel + carboplatin). The primary endpoint was disease-free survival rate at 24 months, whereas secondary endpoints included major pathological response (MPR) and pathologic complete response (pCR) rates, the proportion of patients who achieved tumor downstaging, overall survival, objective response rate (ORR), and adverse effects. PD-L1 status before and after treatment was also determined. Among the 20 patients who received neoadjuvant chemoimmunotherapy, 16 underwent radical resection. The disease control rate and ORR were 90% and 70%, respectively. Among the 16 patients who underwent surgery, 10 (62.5%) and 5 (31.25%) achieved MPR and pCR, respectively. Squamous cell NSCLC exhibited superior response rates compared to adenocarcinoma (pCR 35.7% vs. 0%). Moreover, 14 patients (70%) experienced grade 1 or 2 neoadjuvant treatment-related adverse events (TRAEs), whereas 6 (30%) experienced grade 3 TRAEs. Bronchopleural fistula (BPF) was found in the current study as an adverse reaction of concern. The rate of BPF was 20% (4/20), of which three patients were in grade 1–2, and one patient died. The occurrence of BPF had no significant correlation with basic disease history, nutritional status, anemia, hypoalbuminemia, surgical procedure, pathological remission, and PD-L1 expression. However, during neoadjuvant treatment, no adverse events prompted dose reduction, treatment discontinuation, surgery delay, or death. Although PD-L1 expression may change after chemoimmunotherapy, no regular pattern was noted. PD-L1 expression, neither at baseline nor after neoadjuvant chemoimmunotherapy, was associated with pathological remission. The current study found similar ORR, slightly lower MPR and pCR rates, and lower grade 3 TRAEs among patients with potentially resectable stage IIIA/IIIB NSCLC compared to the NADIM trial, as well as a greater ORR, MPR rate, pCR rate, and grade 3 TRAEs compared to Gao’s study involving sintilimab for Chinese patients with resectable stage IA–IIIB NSCLC. Though neoadjuvant chemoimmunotherapy had been found to promote a high risk of BPF for patients with stage IIIA/IIIB disease, it offered greater potential for radical cure. Therefore, the current study suggests that neoadjuvant chemoimmunotherapy can be a safe approach in increasing the efficiency of treatment and hopefully improving the prognosis of patients with potentially resectable locally advanced NSCLC.
         datePublished:2022-02-22T00:00:00Z
         dateModified:2022-02-22T00:00:00Z
         pageStart:819
         pageEnd:831
         sameAs:https://doi.org/10.1007/s00432-021-03896-w
         keywords:
            Non-small cell lung cancer
            Neoadjuvant
            Chemoimmunotherapy
            Sintilimab
            Oncology
            Cancer Research
            Internal Medicine
            Hematology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-021-03896-w/MediaObjects/432_2021_3896_Fig1_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-021-03896-w/MediaObjects/432_2021_3896_Fig2_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-021-03896-w/MediaObjects/432_2021_3896_Fig3_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-021-03896-w/MediaObjects/432_2021_3896_Fig4_HTML.png
         isPartOf:
            name:Journal of Cancer Research and Clinical Oncology
            issn:
               1432-1335
               0171-5216
            volumeNumber:149
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer Berlin Heidelberg
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Chao Sun
               affiliation:
                     name:The First Hospital of Jilin University
                     address:
                        name:Cancer Center, The First Hospital of Jilin University, Changchun, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Yunpeng Liu
               affiliation:
                     name:The First Hospital of Jilin University
                     address:
                        name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Peng Zhang
               affiliation:
                     name:The First Hospital of Jilin University
                     address:
                        name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Xu Wang
               affiliation:
                     name:The First Hospital of Jilin University
                     address:
                        name:Cancer Center, The First Hospital of Jilin University, Changchun, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Yinghui Xu
               affiliation:
                     name:The First Hospital of Jilin University
                     address:
                        name:Cancer Center, The First Hospital of Jilin University, Changchun, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Xingyu Lin
               affiliation:
                     name:The First Hospital of Jilin University
                     address:
                        name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Xiaobo Ma
               affiliation:
                     name:The First Hospital of Jilin University
                     address:
                        name:Pathological Department, The First Hospital of Jilin University, Changchun, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Ye Guo
               affiliation:
                     name:The First Hospital of Jilin University
                     address:
                        name:Cancer Center, The First Hospital of Jilin University, Changchun, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Shi Qiu
               affiliation:
                     name:The First Hospital of Jilin University
                     address:
                        name:Cancer Center, The First Hospital of Jilin University, Changchun, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Guoguang Shao
               affiliation:
                     name:The First Hospital of Jilin University
                     address:
                        name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Zhiguang Yang
               affiliation:
                     name:The First Hospital of Jilin University
                     address:
                        name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Kewei Ma
               url:http://orcid.org/0000-0003-2987-576X
               affiliation:
                     name:The First Hospital of Jilin University
                     address:
                        name:Cancer Center, The First Hospital of Jilin University, Changchun, China
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial
      description:While some clinical studies have shown that PD-1 and PD-L1 can also be an effective neoadjuvant treatment for early-stage non-small cell lung cancer (NSCLC), no evidence has been available for the use of the PD-1 inhibitor sintilimab combined with chemotherapy as a neoadjuvant treatment for potentially resectable NSCLC in the Chinese population. This prospective, single-center, single-arm, phase 2 clinical trial (registration number: NCT04326153) included treatment-naive patients with potentially resectable NSCLC (stage IIIA/IIIB) who received sintilimab plus nab-paclitaxel and carboplatin for two to three cycles before systematic nodal dissection 30 to 45 days after neoadjuvant treatment. After surgery, patients needed to complete two cycles of adjuvant chemoimmunotherapy (sintilimab + nab-paclitaxel + carboplatin). The primary endpoint was disease-free survival rate at 24 months, whereas secondary endpoints included major pathological response (MPR) and pathologic complete response (pCR) rates, the proportion of patients who achieved tumor downstaging, overall survival, objective response rate (ORR), and adverse effects. PD-L1 status before and after treatment was also determined. Among the 20 patients who received neoadjuvant chemoimmunotherapy, 16 underwent radical resection. The disease control rate and ORR were 90% and 70%, respectively. Among the 16 patients who underwent surgery, 10 (62.5%) and 5 (31.25%) achieved MPR and pCR, respectively. Squamous cell NSCLC exhibited superior response rates compared to adenocarcinoma (pCR 35.7% vs. 0%). Moreover, 14 patients (70%) experienced grade 1 or 2 neoadjuvant treatment-related adverse events (TRAEs), whereas 6 (30%) experienced grade 3 TRAEs. Bronchopleural fistula (BPF) was found in the current study as an adverse reaction of concern. The rate of BPF was 20% (4/20), of which three patients were in grade 1–2, and one patient died. The occurrence of BPF had no significant correlation with basic disease history, nutritional status, anemia, hypoalbuminemia, surgical procedure, pathological remission, and PD-L1 expression. However, during neoadjuvant treatment, no adverse events prompted dose reduction, treatment discontinuation, surgery delay, or death. Although PD-L1 expression may change after chemoimmunotherapy, no regular pattern was noted. PD-L1 expression, neither at baseline nor after neoadjuvant chemoimmunotherapy, was associated with pathological remission. The current study found similar ORR, slightly lower MPR and pCR rates, and lower grade 3 TRAEs among patients with potentially resectable stage IIIA/IIIB NSCLC compared to the NADIM trial, as well as a greater ORR, MPR rate, pCR rate, and grade 3 TRAEs compared to Gao’s study involving sintilimab for Chinese patients with resectable stage IA–IIIB NSCLC. Though neoadjuvant chemoimmunotherapy had been found to promote a high risk of BPF for patients with stage IIIA/IIIB disease, it offered greater potential for radical cure. Therefore, the current study suggests that neoadjuvant chemoimmunotherapy can be a safe approach in increasing the efficiency of treatment and hopefully improving the prognosis of patients with potentially resectable locally advanced NSCLC.
      datePublished:2022-02-22T00:00:00Z
      dateModified:2022-02-22T00:00:00Z
      pageStart:819
      pageEnd:831
      sameAs:https://doi.org/10.1007/s00432-021-03896-w
      keywords:
         Non-small cell lung cancer
         Neoadjuvant
         Chemoimmunotherapy
         Sintilimab
         Oncology
         Cancer Research
         Internal Medicine
         Hematology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-021-03896-w/MediaObjects/432_2021_3896_Fig1_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-021-03896-w/MediaObjects/432_2021_3896_Fig2_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-021-03896-w/MediaObjects/432_2021_3896_Fig3_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-021-03896-w/MediaObjects/432_2021_3896_Fig4_HTML.png
      isPartOf:
         name:Journal of Cancer Research and Clinical Oncology
         issn:
            1432-1335
            0171-5216
         volumeNumber:149
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer Berlin Heidelberg
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Chao Sun
            affiliation:
                  name:The First Hospital of Jilin University
                  address:
                     name:Cancer Center, The First Hospital of Jilin University, Changchun, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Yunpeng Liu
            affiliation:
                  name:The First Hospital of Jilin University
                  address:
                     name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Peng Zhang
            affiliation:
                  name:The First Hospital of Jilin University
                  address:
                     name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Xu Wang
            affiliation:
                  name:The First Hospital of Jilin University
                  address:
                     name:Cancer Center, The First Hospital of Jilin University, Changchun, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Yinghui Xu
            affiliation:
                  name:The First Hospital of Jilin University
                  address:
                     name:Cancer Center, The First Hospital of Jilin University, Changchun, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Xingyu Lin
            affiliation:
                  name:The First Hospital of Jilin University
                  address:
                     name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Xiaobo Ma
            affiliation:
                  name:The First Hospital of Jilin University
                  address:
                     name:Pathological Department, The First Hospital of Jilin University, Changchun, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Ye Guo
            affiliation:
                  name:The First Hospital of Jilin University
                  address:
                     name:Cancer Center, The First Hospital of Jilin University, Changchun, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Shi Qiu
            affiliation:
                  name:The First Hospital of Jilin University
                  address:
                     name:Cancer Center, The First Hospital of Jilin University, Changchun, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Guoguang Shao
            affiliation:
                  name:The First Hospital of Jilin University
                  address:
                     name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Zhiguang Yang
            affiliation:
                  name:The First Hospital of Jilin University
                  address:
                     name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Kewei Ma
            url:http://orcid.org/0000-0003-2987-576X
            affiliation:
                  name:The First Hospital of Jilin University
                  address:
                     name:Cancer Center, The First Hospital of Jilin University, Changchun, China
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Journal of Cancer Research and Clinical Oncology
      issn:
         1432-1335
         0171-5216
      volumeNumber:149
Organization:
      name:Springer Berlin Heidelberg
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:The First Hospital of Jilin University
      address:
         name:Cancer Center, The First Hospital of Jilin University, Changchun, China
         type:PostalAddress
      name:The First Hospital of Jilin University
      address:
         name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
         type:PostalAddress
      name:The First Hospital of Jilin University
      address:
         name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
         type:PostalAddress
      name:The First Hospital of Jilin University
      address:
         name:Cancer Center, The First Hospital of Jilin University, Changchun, China
         type:PostalAddress
      name:The First Hospital of Jilin University
      address:
         name:Cancer Center, The First Hospital of Jilin University, Changchun, China
         type:PostalAddress
      name:The First Hospital of Jilin University
      address:
         name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
         type:PostalAddress
      name:The First Hospital of Jilin University
      address:
         name:Pathological Department, The First Hospital of Jilin University, Changchun, China
         type:PostalAddress
      name:The First Hospital of Jilin University
      address:
         name:Cancer Center, The First Hospital of Jilin University, Changchun, China
         type:PostalAddress
      name:The First Hospital of Jilin University
      address:
         name:Cancer Center, The First Hospital of Jilin University, Changchun, China
         type:PostalAddress
      name:The First Hospital of Jilin University
      address:
         name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
         type:PostalAddress
      name:The First Hospital of Jilin University
      address:
         name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
         type:PostalAddress
      name:The First Hospital of Jilin University
      address:
         name:Cancer Center, The First Hospital of Jilin University, Changchun, China
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Chao Sun
      affiliation:
            name:The First Hospital of Jilin University
            address:
               name:Cancer Center, The First Hospital of Jilin University, Changchun, China
               type:PostalAddress
            type:Organization
      name:Yunpeng Liu
      affiliation:
            name:The First Hospital of Jilin University
            address:
               name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
               type:PostalAddress
            type:Organization
      name:Peng Zhang
      affiliation:
            name:The First Hospital of Jilin University
            address:
               name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
               type:PostalAddress
            type:Organization
      name:Xu Wang
      affiliation:
            name:The First Hospital of Jilin University
            address:
               name:Cancer Center, The First Hospital of Jilin University, Changchun, China
               type:PostalAddress
            type:Organization
      name:Yinghui Xu
      affiliation:
            name:The First Hospital of Jilin University
            address:
               name:Cancer Center, The First Hospital of Jilin University, Changchun, China
               type:PostalAddress
            type:Organization
      name:Xingyu Lin
      affiliation:
            name:The First Hospital of Jilin University
            address:
               name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
               type:PostalAddress
            type:Organization
      name:Xiaobo Ma
      affiliation:
            name:The First Hospital of Jilin University
            address:
               name:Pathological Department, The First Hospital of Jilin University, Changchun, China
               type:PostalAddress
            type:Organization
      name:Ye Guo
      affiliation:
            name:The First Hospital of Jilin University
            address:
               name:Cancer Center, The First Hospital of Jilin University, Changchun, China
               type:PostalAddress
            type:Organization
      name:Shi Qiu
      affiliation:
            name:The First Hospital of Jilin University
            address:
               name:Cancer Center, The First Hospital of Jilin University, Changchun, China
               type:PostalAddress
            type:Organization
      name:Guoguang Shao
      affiliation:
            name:The First Hospital of Jilin University
            address:
               name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
               type:PostalAddress
            type:Organization
      name:Zhiguang Yang
      affiliation:
            name:The First Hospital of Jilin University
            address:
               name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Kewei Ma
      url:http://orcid.org/0000-0003-2987-576X
      affiliation:
            name:The First Hospital of Jilin University
            address:
               name:Cancer Center, The First Hospital of Jilin University, Changchun, China
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Cancer Center, The First Hospital of Jilin University, Changchun, China
      name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
      name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
      name:Cancer Center, The First Hospital of Jilin University, Changchun, China
      name:Cancer Center, The First Hospital of Jilin University, Changchun, China
      name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
      name:Pathological Department, The First Hospital of Jilin University, Changchun, China
      name:Cancer Center, The First Hospital of Jilin University, Changchun, China
      name:Cancer Center, The First Hospital of Jilin University, Changchun, China
      name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
      name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
      name:Cancer Center, The First Hospital of Jilin University, Changchun, China
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(152)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js
Video.js

CDN Services {📦}

Crossref

3.78s.

LINK . SPRINGER . COM {}